Ascletis Pharma Inc Ordinary Shares 01672
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 1.05B
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- 229.46
- Price/Sales
- 7,996.30
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Ascletis Pharma Inc is an investment holding company. The company is a fully integrated biotechnology company focused on the development and commercialization of potential therapeutics to treat metabolic diseases. Along with its subsidiaries, it is engaged in the research, development, production, marketing, and sale of pharmaceutical products. The company uses its Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP) technologies and Peptide Oral Transport ENhancement Technology (POTENT) to develop multiple drug candidates in-house, including both small molecules and peptides. The drug candidates of the company in the pipeline in their different stages of development such as ASC30, ASC47, ASC39, ASC36i, ASC35, ASC50, and among others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 217
- Website
- https://www.ascletis.com
Valuation
|
Metric
|
01672
|
|---|---|
Price/Earnings (Normalized) | 229.46 |
Price/Book Value | 3.39 |
Price/Sales | 7,996.30 |
Price/Cash Flow | — |
Price/Earnings
01672
Financial Strength
|
Metric
|
01672
|
|---|---|
Quick Ratio | 12.89 |
Current Ratio | 12.92 |
Interest Coverage | −4,410.26 |
Quick Ratio
01672
Profitability
|
Metric
|
01672
|
|---|---|
Return on Assets (Normalized) | −26.43% |
Return on Equity (Normalized) | −28.35% |
Return on Invested Capital (Normalized) | −31.99% |
Return on Assets
01672
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|>GWg<>j | LOCK|#W?kk | $128B | |||
| Moderna Inc
MRNA
| LOCK|x&#G&@ | LOCK|&Y | $76B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|&@<y^pz | LOCK|#?t< | $76B | |||
| argenx SE ADR
ARGX
| LOCK|$$W>!$R | LOCK|z$b | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|kY>@%TQ | LOCK|!m | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|W&Wz<r | LOCK|W!#?$ | $29B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|V?@H>$wy | LOCK|j^lQ> | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|j#!S$z | LOCK|mV | $24B | |||
| Incyte Corp
INCY
| LOCK|tJ>M>&< | LOCK|@t< | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|KY&?$S | LOCK|Zb! | $15B |
United States